Talazoparib/Enzalutamide Improves Long-Term QOL in Metastatic CRPC
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.